Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health
Headline: Directs modernization of U.S. influenza vaccine system for pandemics
What it does: Agencies must develop and implement a national plan to modernize vaccine manufacturing and expand faster, non-egg production.
- Aims to expand faster, non-egg vaccine production across domestic manufacturers
- Requires cost estimates and procurement shifts for military and veterans' vaccine purchases
- Directs outreach and studies to increase vaccination and improve vaccine matching
Summary
This order directs the federal government to modernize how influenza vaccines are developed and made, reducing reliance on egg-based production and promoting faster, scalable technologies such as cell-based and recombinant methods.
It creates a National Influenza Vaccine Task Force co-chaired by the Departments of Defense and Health and Human Services to produce a five-year plan, cost estimates, and yearly updates. The order affects federal health programs, military and veterans' vaccine procurement, vaccine manufacturers, and public vaccination efforts.
Its purpose is to improve seasonal vaccine effectiveness and strengthen national security by preparing for rapid pandemic response.
Ask about this order
Ask questions about this executive order and its implications.
What agencies are affected by this order?
How does this order change existing policy?
What are the practical implications of this order?